Navigation Links
Indevus in Medical News

Endo Pharmaceuticals Solutions (Formerly Indevus Pharmaceuticals, Inc.) Announces Commencement of Offer to Purchase Its 6.25% Convertible Senior Notes Due 2009

LEXINGTON, Mass., March 25 /PRNewswire/ -- Endo Pharmaceuticals Solutions Inc. (formerly known as Indevus Pharmaceuticals, Inc.) today commenced an offer to purchase any or all of its outstanding 6.25% Convertible Senior Notes due 2009 in accordance with the indenture governing the Notes, as a res...

Endo Pharmaceuticals Completes Acquisition of Indevus Pharmaceuticals

CHADDS FORD, Pa., March 23 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals (Nasdaq: ENDP ) today announced the successful completion of its acquisition of Indevus Pharmaceuticals, Inc. Endo acquired Indevus through a tender offer and subsequent merger upon which Indevus became a wholly owned sub...

Endo Pharmaceuticals Announces Successful Completion of Tender Offer for Indevus Pharmaceuticals

CHADDS FORD, Pa., March 19 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals (Nasdaq: ENDP ) today announced the successful completion of the tender offer by its wholly owned subsidiary, BTB Purchaser Inc., for all of the outstanding shares of common stock of Indevus Pharmaceuticals, Inc. (Nasdaq: ...

Endo Pharmaceuticals Announces Extension of its Tender Offer for Shares of Indevus Pharmaceuticals

CHADDS FORD, Pa., March 2 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals (Nasdaq: ENDP ) announced today that it has extended the subsequent offering period of the tender offer by its wholly owned subsidiary, BTB Purchaser Inc., for all of the outstanding shares of common stock of Indevus Pharma...

Endo Pharmaceuticals to Acquire Indevus Pharmaceuticals

Acquisition Adds Marketed Products and Specialty Sales Force in Urology and Endocrinology, Novel Drug-Delivery Technology Combined Pipeline to Include Nine FDA-Approved Therapeutics Conference Call Scheduled for Today at 5:30 pm EST CHADDS FORD, Pa. and LEXINGTON, Mass., Jan. 5 /PR...

FDA Accepts New Drug Application for NEBIDO(R) Submitted by Indevus

LEXINGTON, Mass., Nov. 1 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV ) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Company's New Drug Application (NDA) for NEBIDO(R), its long-acting injectable testosterone preparation...

Men with Low Testosterone See Multiple Doctors Before Being Diagnosed; Many Dissatisfied with Current Treatment Options

... the possibility that the transaction will not be completed, or if completed, not completed on a timely basis; the possibility that the acquisition of indevus is not complementary to Endo; the inherent uncertainty of the timing and success of, and expense associated with, research, development, regulatory ap...

Endo to Present at Bank of America and Merrill Lynch 2009 Health Care Conference

... the possibility that the transaction will not be completed, or if completed, not completed on a timely basis; the possibility that the acquisition of indevus is not complementary to Endo; the inherent uncertainty of the timing and success of, and expense associated with, research, development, regulatory ap...

Endo Pharmaceuticals Reports First Quarter 2009 Financial Results

...cluding results beginning on February 23, 2009 for indevus Pharmaceuticals, which Endo acquired during the qu...ucts recently obtained through our acquisition of indevus Pharmaceuticals, Inc. for the period February 23, ...r certain generic products. Acquisition of indevus Pharmaceuticals, Inc. During the first quart...

Testosterone Undecanoate Achieves and Maintains Normal Testosterone Levels in Hypogonadal Men With Five Injections Per Year, New Data Show

... the possibility that the transaction will not be completed, or if completed, not completed on a timely basis; the possibility that the acquisition of indevus is not complementary to Endo; the inherent uncertainty of the timing and success of, and expense associated with, research, development, regulatory ap...
Indevus in Medical Technology

FDA Accepts Complete Response Submission to New Drug Application for NEBIDO(R)

...Nasdaq: ENDP ) and its majority-owned subsidiary indevus Pharmaceuticals, Inc. (Nasdaq: IDEV ) announced ... NEBIDO was licensed by BayerSchering Pharma AG to indevus Pharmaceuticals, a majority interest in which Endo...icals, is available at www.endo.com . About indevus ...

Endo Pharmaceuticals Announces Research Collaborations to Develop Novel Pain Treatments and Discover Potential Cancer Treatments

... the possibility that the transaction will not be completed, or if completed, not completed on a timely basis; the possibility that the acquisition of indevus is not complementary to Endo; the potential that market segment growth will not follow historical patterns; general industry conditions and competitio...

Indevus Pharmaceuticals Announces PRO 2000 Found to Show Promise in Large HIV Prevention Study

...LEXINGTON, Mass., Feb. 9 /PRNewswire-FirstCall/ -- indevus Pharmaceuticals, Inc. (Nasdaq: IDEV ) announced ...00 be shown conclusively to be safe and effective, indevus intends to seek worldwide marketing approvals, and... used in 73 low-income countries. About indevus ...

Endo Pharmaceuticals and Alexza Pharmaceuticals Conclude Research Collaboration

... the possibility that the transaction will not be completed, or if completed, not completed on a timely basis; the possibility that the acquisition of indevus is not complementary to Endo; the potential that market segment growth will not follow historical patterns; general industry conditions and competitio...

Indevus Announces Agreement With Teva to Develop Pagoclone for the Treatment of Stuttering

... LEXINGTON, Mass., Sept. 26 /PRNewswire/ -- indevus Pharmaceuticals, Inc. (Nasdaq: IDEV ) today annou... for the exclusive, worldwide rights to pagoclone. indevus previously announced promising data from its 8-wee...le regulatory clearances and customary conditions, indevus will conduct and Teva will reimburse...

Indevus Pharmaceuticals Announces Completion of Enrollment in Phase III Trial of PRO 2000

...ended in July 2007. Completion of the HPTN 035 trial is expected later this year. Results from the trial are expected by early 2009. About Indevus indevus Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in the acquisition, development and commercialization of products to treat conditi...

Indevus Presents Successful Phase III NEBIDO(R) Data at American Urological Association

... in the growing market for testosterone therapies. indevus acquired U.S. rights to NEBIDO from Bayer Schering...tment with testosterone therapy. About Indevus indevus Pharmaceuticals, Inc. is a specialty pharmaceutica...itions and related uncertainties; and other risks. indevus undertakes no obligation to publicly update any fo...

Indevus Pharmaceuticals Provides Update on PRO 2000 Program

...5 trial is expected this summer. About Indevus indevus Pharmaceuticals, Inc. is a specialty pharmaceutica...itions and related uncertainties; and other risks. indevus undertakes no obligation to publicly update any fo...on, future events or otherwise. Contact: For indevus Michael W. Rogers Executive Vice President and C...

Indevus Reports Additional Positive Phase III Trial Data for NEBIDO(R)

...ing market for testosterone replacement therapies. indevus acquired U.S. rights to NEBIDO from Bayer Schering...estosterone replacement therapy. About Indevus indevus Pharmaceuticals, Inc. is a specialty pharmaceutica...itions and related uncertainties; and other risks. indevus undertakes no obligation to publicly update any fo...

Indevus Pharmaceuticals Reports Positive Results of Phase II Octreotide Implant Trial

...he United States. About Octreotide Implant The indevus octreotide implant is a proprietary formulation of...e (GH), over a six month period. About Indevus indevus Pharmaceuticals, Inc. is a specialty pharmaceutica...elated litigation; the risk that the businesses of indevus and Valera Pharmaceuticals, Inc. will not be integ...
Indevus in Biological News

MetaChip provides quick, efficient toxicity screening of potential drugs

...ting two topical microbicides with differing mechanisms of action," she adds. The microbicides to be tested are PRO 2000 and BufferGel. Produced by indevus Pharmaceuticals, Lexington, MA, PRO 2000 has shown activity against HIV and other STIs in both laboratory and animal testing. It is believed to act by...

International trial of two microbicides begins

...ting two topical microbicides with differing mechanisms of action," she adds. The microbicides to be tested are PRO 2000 and BufferGel. Produced by indevus Pharmaceuticals, Lexington, MA, PRO 2000 has shown activity against HIV and other STIs in both laboratory and animal testing. It is believed to act by...

Topical treatment shown to inhibit HIV and herpes simplex virus infection

...e study, which was funded by the National Institutes of Health (NIH) investigated the efficacy of PRO 2000, a topical microbicide under development by indevus Pharmaceuticals, Inc. "There is an urgent need for the development of safe and effective vaginal microbicides," Marla Keller, M.D., Assistant Profes...
Indevus in Biological Technology

Endo Pharmaceuticals Extends Subsequent Offering Period for Indevus Shares Until 5:00 pm EDT on Wednesday, March 18, 2009

Announces that Approximately 89.3 Percent of Outstanding Indevus Shares Have Been Accepted for Purchase CHADDS FORD, Pa., March 16 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals (Nasdaq: ENDP ) announced today that, as of 5:00 p.m., New York City time, on March 13, 2009, approximately 71,00...

Endo Pharmaceuticals Successfully Completes Tender Offer for Shares of Indevus Pharmaceuticals and Announces Subsequent Offering Period

CHADDS FORD, Pa., Feb. 23 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals (Nasdaq: ENDP ) today announced the successful completion of the tender offer by its wholly owned subsidiary, BTB Purchaser Inc., for all of the outstanding shares of common stock of Indevus Pharmaceuticals, Inc. (Nasdaq: ...

125 Indevus Sales Representatives to Provide Community Service in New Orleans for Jericho Road Episcopal Housing Initiative

Indevus encouraging other companies across the country to hold their events in New Orleans and to bring their helping hearts and hands LEXINGTON, Mass., March 20 /PRNewswire-FirstCall/ -- As part of its annual sales meeting being held in New Orleans for the first time, Indevus Pharmaceutic...

Endo Pharmaceuticals Reports Strong Second Quarter 2009 Financial Results

...er of 2009, including a full quarter of results of indevus Pharmaceuticals, Inc., which Endo acquired during ... areas that we've entered, with our acquisition of indevus Pharmaceuticals, Inc. earlier this year. Our new ...ue of contingent consideration associated with the indevus transaction and the addition of milestone payments...

New Report Just Published: World Prostate Cancer Therapeutics Market Report

...ch Inc., GlaxoSmithKline Plc., Immunomedics, Inc., indevus Pharmaceuticals Inc., Novartis AG, OSI Pharmaceuti...xpands into France with Sonablate(R) 500 II-81 indevus Enters into Agreement to Takeover Valera II-82 ... (UK) II-95 Immunomedics, Inc. (USA) II-95 indevus Pharmaceuticals Inc. (USA) II-95 Novartis AG (...

Endo Pharmaceuticals Appoints Dr. Nancy Hutson to Board of Directors

... the possibility that the transaction will not be completed, or if completed, not completed on a timely basis; the possibility that the acquisition of indevus is not complimentary to Endo; the inherent uncertainty of the timing and success of, and expense associated with, research, development, regulatory ap...

Indevus Pharmaceuticals Announces Release of 2008 Annual Report

...EXINGTON, Mass., Jan. 27 /PRNewswire-FirstCall/ -- indevus Pharmaceuticals, Inc. (Nasdaq: IDEV ) today anno...t (781) 861-8444 or by mailing written requests to indevus Pharmaceuticals, Inc., Attention Investor Relation...Global Market under the symbol "IDEV." About indevus Pharmaceuticals ...

Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results

...reement with Teva, this trial will be conducted by indevus and funded by Teva. The results of this trial pro...for 30 days following the live call. About indevus indevus Pharmaceuticals, Inc. is a specialty pharmaceutica...

Indevus Pharmaceuticals to Present at Upcoming Investor Conferences

... web cast live and may be accessed by visiting the Investors section of the indevus website at http://www.indevus.com . About Indevus indevus Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in the ...

Indevus and FDA Agree on Path Forward for NEBIDO(R)

... of serious post-injection, oil-based reactions. indevus and FDA also agreed on an education plan to minimi...rity of the serious oil- based reactions. Further, indevus and FDA agreed to obtain skin-testing data to char...drug or any of its excipients in certain patients. indevus has also agreed to conduct a large, simple post- m...
Other Tags
(Date:4/17/2014)... the most popular vaccine brands for children may not ... overlooking some cost factors when choosing vaccines, driving the ... according to a new study by University of Illinois ... be driven by numerous factors," says Sheldon H. Jacobson, ... computer science and of mathematics at the U. of ...
(Date:4/17/2014)... issue of Experimental Biology and Medicine ... Gaskins and Paul Kenis in the Institute of ... University of Illinois Urbana-Champaign describe their recent work ... a variety of cell functions including energy metabolism, ... roles in regulating normal cellular behavior, redox status ...
(Date:4/17/2014)... recent papers by a University of Colorado School ... develop treatments or vaccines for Dengue fever, West ... disease-causing flaviviruses. , Jeffrey S. Kieft, PhD, associate ... School of Medicine and an early career scientist ... recently published articles in the scholarly journals ...
(Date:4/17/2014)... Bonheur Children,s Hospital Pediatrician-in-Chief Jon McCullers, MD, was ... April issue of Nature Reviews Microbiology , ... Dr. McCullers, a world-renowned infectious disease specialist, and ... University of Tennessee Health Science Center, analyzed the ... 1957 and 1968 pandemics, as well as more ...
(Date:4/17/2014)... 2014U.S. military personnel who served in Iraq and ... brain injury (TBI) were compared to military personnel ... reasons. Differences in measures of overall disability, cognitive ... injury are reported in an article in ... Mary Ann Liebert, Inc., publishers. The article is ...
Breaking Medicine News(10 mins):Health News:Study recalculates costs of combination vaccines 2Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:CU researchers discover target for treating dengue fever 2Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2
(Date:4/17/2014)... Razzari of the nergie Matriaux Tlcommunications Research Centre ... John R. Evans Leaders Fund of the Canada ... state-of-the-art biotech and nanophotonics equipment. To this funding ... de l,Enseignement suprieur, de la Recherche, de la ... laboratories will help us develop new approaches for ...
(Date:4/17/2014)... Kansas State University engineer has developed a patented ... improvised explosive devices. The same technique could help ... Steven M. and Kay L. Theede chair in ... engineering, and his research team have created a ... in car trunks. The distance detection method ...
(Date:4/17/2014)... This news release is available in German . ... fails to pay the protection money demanded of him, he ... are seldom required, however, as fear of the consequences is ... is observed in parasitic birds, which lay their eggs in ... egg out, the brood parasites take their revenge by destroying ...
Breaking Biology News(10 mins):New state-of-the-art biotech and nanotech equipment for INRS 2Patented research remotely detects nitrogen-rich explosives 2Fear of the cuckoo mafia 2Fear of the cuckoo mafia 3
Other Contents